Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Dimerix Bioscience Pty Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 2 distinct examiners in 2 distinct art units. BORI, IBRAHIM D is the busiest examiner, with 1 pending matter. The data shows distribution across separate examination environments.
Prosecution counsel should maintain a consistent scientific description where the matters concern related biotechnology or pharmaceutical subject matter, while tailoring each response to its assigned examiner and art unit. Claim distinctions may depend on biological activity, treatment context, composition, or supporting experimental disclosure, so amendments should be tied carefully to the specification. The separate assignments make it useful to compare objection patterns without assuming identical treatment. Interview preparation and claim strategy should remain matter specific.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18774024 | METHOD FOR TREATING INFLAMMATORY DISORDERS | BORI, IBRAHIM D | — |
| 18718617 | COMPOSITIONS COMPRISING A CHEMOKINE RECEPTOR PATHWAY INHIBITOR | PACKARD, BENJAMIN J | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18774024 | METHOD FOR TREATING INFLAMMATORY DISORDERS | BORI, IBRAHIM D | 1629 | DP | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18718617 | COMPOSITIONS COMPRISING A CHEMOKINE RECEPTOR PATHWAY INHIBITOR | PACKARD, BENJAMIN J | 1612 | §103 | Final Rejection | — | Pending | Jun 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDimerix Bioscience Pty Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ibrahim D Bori has the most, with 1 of Dimerix Bioscience Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
